{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-119165","form_type":"8-K","ticker":"NWBO","cik":"0001072379","company_name":"NORTHWEST BIOTHERAPEUTICS INC","filed_at":"2023-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.130471+00:00","generated_at":"2026-06-08T00:50:14.157850+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"NWBO enters $11M loan with Streeterville Capital; 8% interest, 24-month maturity","bullets":["Loan amount $11,005,000 from Streeterville Capital; 24-month maturity; repayments begin Nov 2024.","Interest rate 8% per annum; 10% original issue discount; prepayment allowed with 10% charge.","Loan amortized in 12 equal monthly installments at 110% of pro rata principal plus accrued interest.","Proceeds used for ongoing business operations; customary default provisions included."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-119165","json":"https://secwatch.observer/filing/0001104659-23-119165.json","markdown":"https://secwatch.observer/filing/0001104659-23-119165.md","text":"https://secwatch.observer/filing/0001104659-23-119165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1072379/000110465923119165/0001104659-23-119165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1072379/000110465923119165/tm2330851d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T00:50:14.157850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67d6cc595b8e7be8d6096a3bdf9e86b9269cfb14","claim":"NORTHWEST BIOTHERAPEUTICS INC incurred loan of $11,005,000 with Streeterville Capital, LLC at 8% per annum maturing 24 months.","evidence_excerpt":"On November 10, 2023, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000. The Loan Agreement has a maturity of 24 months. Repayments do not start until November 10, 2024. Following November 10, 2024, the Loan Agreement will be amortized in 12 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. Interest on the Loan Agreement accrues at a rate of 8% per annum, and the Loan Agreement includes an original issue discount of ten percent.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465923119165/0001104659-23-119165-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$11,005,000"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Rate","value":"8% per annum"},{"label":"Maturity","value":"24 months"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"629ec45bb52150d2314c8ae03ab5e0d743275e6f","claim":"NORTHWEST BIOTHERAPEUTICS INC entered into Commercial Loan Agreement and Note with Streeterville Capital, LLC valued at $11,005,000 (effective 2023-11-10).","evidence_excerpt":"On November 10, 2023, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465923119165/0001104659-23-119165-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Value","value":"$11,005,000"},{"label":"Effective","value":"2023-11-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}